688137 近岸蛋白
2024/03 - 三个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-0.1200.5857.08864.383174.045
总资产报酬率 ROA (%)-0.1140.5556.37443.50381.439
投入资产回报率 ROIC (%)-0.1160.5656.60951.428145.464

边际利润分析
销售毛利率 (%)68.27875.66886.32287.69489.255
营业利润率 (%)-19.1584.25139.64951.76152.375
息税前利润/营业总收入 (%)-50.368-13.88237.41051.92254.110
净利润/营业总收入 (%)-10.0838.38434.29343.58246.178

收益指标分析
经营活动净收益/利润总额(%)166.186159.623102.128108.514105.786
价值变动净收益/利润总额(%)-50.250276.2973.9160.4830.271
营业外收支净额/利润总额(%)9.173-4.6571.215-0.419-0.045

偿债能力分析
流动比率 (X)36.00341.30433.3514.6282.161
速动比率 (X)34.49339.60832.1474.1101.883
资产负债率 (%)5.2404.8035.70929.88340.036
带息债务/全部投入资本 (%)0.9180.6360.6324.39811.233
股东权益/带息债务 (%)10,485.22615,201.72915,250.5371,772.249778.877
股东权益/负债合计 (%)1,808.2731,981.8661,651.570234.639149.778
利息保障倍数 (X)1.7200.774-13.720137.72130.777

营运能力分析
应收账款周转天数 (天)217.266218.365146.60362.97227.313
存货周转天数 (天)932.925782.545568.439239.151285.733